HCC: AGA issues guidelines for DAA timing, surveillance

  • Gastroenterology

  • Oncology guidelines update
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • The American Gastroenterological Association (AGA) has released a practice update that includes recommendations for timing of HCV direct-acting antiviral (DAA) therapy in patients with hepatocellular carcinoma (HCC).

Why this matters

  • The clinical practice update presents available evidence regarding DAAs and HCC incidence/recurrence.

Key points

  • Treatment with DAAs is associated with a reduction in HCC risk, regardless of the presence of cirrhosis.
  • Patients with advanced liver fibrosis or cirrhosis should undergo HCC surveillance before initiating DAA and should remain in surveillance.
  • Surveillance should include ultrasound, with or without Alpha-fetoprotein (AFP) every 6 months.
  • Patients with HCC:
    • Those eligible for curative resection or ablation should defer DAA until after treatment.
    • Those eligible for liver transplantation should time DAA therapy based on wait times, availability of HCV-positive organs, and liver dysfunction.
    • In active, immediate, or advanced HCC, benefit and cost-effectiveness of DAA are unclear.
    • In patients with complete response to HCC therapy, it is unclear how DAA affects recurrence risk. DAAs should not be withheld, but can be delayed 4-6 months. Surveillance should continue indefinitely with dynamic contrast-enhanced CT or MRI every 3-6 months.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit